Say Hello!
Don’t be shy.

0333 323 1843

[email protected]


BioCity Group HQ:
Pennyfoot Street

Absynth Biologics

Absynth Biologics

Home > Investment> Absynth Biologics

Absynth Biologics are pioneering the discovery and development of innovative vaccines to prevent and treat life threatening bacterial infections such as S. aureus and C. difficile for which there are currently no marketed vaccines. Their highly differentiated approach, using antigen targets which harness the immune system in a multimodal fashion, will create differentiated vaccines. Absynth team comprise world leading microbiology and infection expertise.


BioCity invested in Absynth because of the courageous and unique approach they have taken in developing a much-needed solution to target colonisation.